Schrodinger shares came under pressure after Citi pulled back its bullish call, cutting the stock to ‘Neutral’ from ‘Buy’ and slashing its price target to $20 from $35. The firm said recent stumbles ...

Jenny Herman, the Senior Vice President and Controller at Schrodinger, Inc. (NASDAQ:SDGR), recently sold 859 shares of the company's common stock. The shares were sold at a price of $24.43 each, ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant Novartis that could generate $2.3 billion in milestone and royalty payments ...

Schrödinger delivered strong Q1 results, with robust software growth and improving margins, despite a tough macro environment. Regulatory changes, especially the FDA's move away from animal testing, ...